- cafead May 21, 2024 at 07:23: PM
via The rivalry between Eli Lilly and Novo Nordisk
extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s.
The two drugmakers are also competing to develop once-weekly insulin injections.
Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes.
article source
extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s.
The two drugmakers are also competing to develop once-weekly insulin injections.
Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes.
article source